Turn Announces Final Stage 2 Design and Expansion of Phase 2 Program

Turn Therapeutics revealed the final adaptive Stage 2 design for its atopic dermatitis drug GX-03 after observing clinically meaningful efficacy across various disease severities. The trial expansion and use of an FDA-recognized statistical method significantly strengthen the outlook for regulatory approval.